Antidiabetic Melanotan 2 99% GLP-1 API Powder

Product Details
Customization: Available
Function: Specialist Drugs, Antidiabetic Medication
Certification: GMP
Gold Member Since 2009

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Number of Employees
80
Year of Establishment
2009-01-21
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
  • Antidiabetic Melanotan 2 99% GLP-1 API Powder
Find Similar Products

Basic Info.

Type
API Raw Materials
State
Powder
C187h291n45o59
C187h291n45o59
Transport Package
Box, Bags
Specification
25kg/50kg/100kg
Trademark
ECHEMI
Origin
China
HS Code
30049099

Product Description

Product Name: peptide-1 (GLP-1)
Molecular Formula: C187H291N45O59
Formula Weight: 4113.57754
Appearance: Solid powder
Purity: >98%
Storage: Dry, dark, and at 0 - 4 C for the short term (days to weeks) or -20 C for the long term (months to years).
Solubility: Soluble in DMS
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.


WHAT IS peptide-1 (GLP-1) AND HOW DOES IT WORK?

Peptide-1 (GLP-1) is a prescription medication used to treat Type 2 Diabetes Mellitus and for Weight Management

WHAT ARE DOSAGES OF peptide-1 (GLP-1)?

Adult dosage

Injection, prefilled, single-dose pen 

  • 2mg/1.5mL (1.34mg/mL); delivers doses of 0.25mg, 0.5mg, or 1mg per injection
  • 4mg/3mL (1.34mg/mL); delivers 1 mg per injection

Injection, prefilled, single-dose pen 

  • 0.25mg/0.5mL
  • 0.5mg/0.5mL
  • 1mg/0.5mL
  • 1.7mg/0.75mL
  • 2.4mg/0.75mL

Oral tablet 

  • 3mg
  • 7mg
  • 14mg

Type 2 Diabetes Mellitus

Adult dosage

SC

  • 0.25 mg SC once per week for 4 weeks initially; then increase to 0.5 mg per week
  • If glycemic control is not achieved after at least 4 weeks on a 0.5-mg dose, can increase to 1 mg once weekly
  • Note: the initial 0.25-mg dose is intended for treatment initiation and is not effective for glycemic control

Oral

  • Initial: 3 mg orally once daily for 30 days; then the 3-mg dose is intended for treatment initiation and is not effective for glycemic control
  • After 30 days on 3 mg/day: increase to 7 mg orally once daily
  • After 30 days on 7 mg/day: may increase the dose to 14 mg orally once daily if additional glycemic control needed
  • Note: Taking two 7-mg tablets to achieve a 14 mg dose is not recommended

Switching between peptide-1 (GLP-1) and Ryhelsus (orally)

  • Taking 14 mg/day orally: Transition to 0.5 mg SC once weekly on the day after the last oral dose
  • Taking 0.5 mg/week SC: Transition to 7 mg or 14 mg orally starting up to 7 days after last SC injection
  • There is no equivalent oral dose for the 1-mg SC dose

Weight Management

Adult dosage

  • Initiate with a low dose and gradually escalate to a maintenance dose of 2.4 mg/week SC to minimize GI adverse reactions
  • If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decrease to 1.7 mg once weekly, for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once-weekly; discontinue if not tolerated after the second attempt 
  • Weeks 1-4: 0.25 mg
  • Weeks 5-8: 0.5 mg
  • Weeks 9-12: 1 mg
  • Weeks 13-16: 1.7 mg
  • Week 17 onward: 2.4 mg (maintenance)
Antidiabetic Melanotan 2 99% GLP-1 API PowderAntidiabetic Melanotan 2 99% GLP-1 API Powder
Antidiabetic Melanotan 2 99% GLP-1 API PowderAntidiabetic Melanotan 2 99% GLP-1 API Powder

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier